CompletedNCT05279313
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
Researchers studied Centanafadine Hydrochloride, tracking side effects to assess long-term safety and tolerability in children and adolescents with ADHD.
Medication studyAges 4–18Canada + United States
Understand this study
What did researchers investigate?
Researchers studied Centanafadine Hydrochloride, tracking side effects to assess long-term safety and tolerability in children and adolescents with ADHD.
Who was this study for?
Listed age limits: 4 years to 18 years.
- Listed locations
- Dothan and 85 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 24, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 680
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- From 4 Years to 18 Years
- Official registry ID
- NCT05279313
- Official title
Show the full official title
A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability of Once Daily Centanafadine Capsules in Children and Adolescents (4 to 17 Years of Age, Inclusive) With Attention-deficit/Hyperactivity Disorder (ADHD).
Get this study by email
Recruitment & locations
CompletedDothan, United States · Saraland, United States · Phoenix, United States
64 more locations
- Little Rock, United States
- Beverly Hills, United States
- Culver City, United States
- Imperial, United States
- Long Beach, United States
- Orange, United States
- Santa Ana, United States
- Santee, United States
- Upland, United States
- Colorado Springs, United States
- Norwich, United States
- Gainesville, United States
- Hialeah, United States
- Jacksonville, United States
- Lauderhill, United States
- Maitland, United States
- Miami, United States
- Miami Lakes, United States
- Orange City, United States
- Orlando, United States
- Palm Bay, United States
- Tampa, United States
- West Palm Beach, United States
- Atlanta, United States
- Decatur, United States
- Meridian, United States
- Chicago, United States
- Naperville, United States
- Evansville, United States
- Overland Park, United States
- Bowling Green, United States
- Owensboro, United States
- Springfield, United States
- Bloomfield, United States
- Flowood, United States
- Saint Charles, United States
- Lincoln, United States
- Las Vegas, United States
- Albuquerque, United States
- New York, United States
- Charlotte, United States
- Cincinnati, United States
- Cleveland, United States
- West Chester, United States
- Oklahoma City, United States
- Media, United States
- East Greenwich, United States
- North Charleston, United States
- Memphis, United States
- Austin, United States
- Baytown, United States
- Bellaire, United States
- Dallas, United States
- DeSoto, United States
- Friendswood, United States
- Houston, United States
- Plano, United States
- San Antonio, United States
- The Woodlands, United States
- West Jordan, United States
- Bellevue, United States
- Everett, United States
- Ottawa, Canada
- San Juan, Puerto Rico
Questions about this study
What did researchers investigate?
Researchers studied Centanafadine Hydrochloride, tracking side effects to assess long-term safety and tolerability in children and adolescents with ADHD.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Centanafadine Hydrochloride.
Who was this study for?
Listed age limits: 4 years to 18 years.
